title: Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression.
abstract: Levothyroxine (L-T4)-based suppression of thyrotropin (TSH) secretion is widely used to prevent the growth of benign thyroid nodules, although the effectiveness of this approach has been demonstrated only in a subset of patients. In this study, we analyzed the in vivo effects of L-T4-mediated TSH suppression on elements of insulin/IGF-1-dependent growth-regulating pathways in tissues from patients with benign thyroid nodules. Nodular and non-nodular tissue specimens were collected from 63 patients undergoing thyroidectomy. 32 had received preoperative TSH suppressive therapy with TSH levels consistently below 0.5 mU/l (L-T4 group). TSH suppression had not been used in the other 31, and their TSH levels were normal (0.8-4 mU/l (control group). Quantitative RT-PCR was used to measure mRNA levels for TSH receptor, IGF1, IGF-1 receptor, insulin receptor, insulin receptor substrate 1 in nodular and non-nodular tissues from the 2 groups. Akt and phosphorylated Akt protein levels were detected by Western blot. Mean levels of mRNA for all genes tested were similar in the 2 groups, in both nodular and non-nodular tissues. The 2 groups were also similar in terms of phosphorylated Akt protein levels (measured by densitometric scan in 10 randomly selected nodules from each group). This is the first demonstration based on the study of human thyroid tissues that TSH suppression does not affect the expression of components of the insulin/IGF-1-dependent signaling pathways regulating thyrocyte growth. This may explain the lack of effectiveness of TSH-suppressive therapy in a substantial percentage of benign thyroid nodules.
authors.affiliation: Dipartimento di Scienze Cliniche, Università di Roma Sapienza, Roma, Italy.
authors.forename: M L
authors.initials: ML
authors.lastname: Sponziello
authors.forename: R
authors.initials: R
authors.lastname: Bruno
authors.forename: C
authors.initials: C
authors.lastname: Durante
authors.forename: M
authors.initials: M
authors.lastname: D'Agostino
authors.forename: R
authors.initials: R
authors.lastname: Corradino
authors.forename: P
authors.initials: P
authors.lastname: Giannasio
authors.forename: E
authors.initials: E
authors.lastname: Ciociola
authors.forename: E
authors.initials: E
authors.lastname: Ferretti
authors.forename: M
authors.initials: M
authors.lastname: Maranghi
authors.forename: A
authors.initials: A
authors.lastname: Verrienti
authors.forename: G
authors.initials: G
authors.lastname: De Toma
authors.forename: S
authors.initials: S
authors.lastname: Filetti
authors.forename: D
authors.initials: D
authors.lastname: Russo
mesh_terms: D000328:Adult; D000368:Aged; D015536:Down-Regulation; D005260:Female; D015870:Gene Expression; D006044:Goiter, Nodular / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism* / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism*; D017978:Receptors, Growth Factor / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction; D013965:Thyroidectomy; D013972:Thyrotropin / Q000378:metabolism*; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: D017978:Receptors, Growth Factor; D013972:Thyrotropin; D051057:Proto-Oncogene Proteins c-akt; D013974:Thyroxine